How much cash does OS Therapies generate?

OS Therapies (OSTX) generated -$15.4M in operating cash flow over the trailing twelve months.

What is OS Therapies's free cash flow?

OS Therapies's free cash flow was -$14.7M over the trailing twelve months.

Where does OS Therapies's cash flow data come from?

Every line is extracted from OS Therapies's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

OS Therapies OSTX Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$35.27M-22.7%	-$28.75M-57.3%	-$18.28M-28.0%	-$14.28M-26.4%	-$11.3M-27.2%
Depreciation and amortization	$487.33K+34.2%	$363.09K+51.6%	$239.54K+109%	$114.6K+4,022%	$2.78K0.0%
Stock-based compensation	$4.76M+11.6%	$4.27M+56.3%	$2.73M+37.8%	$1.98M+73.4%	$1.14M+326%
Amortization of debt issuance costs	——	——	——	——	-$275.62K-119%
Change in accrued liabilities	——	——	——	——	——
Change in prepaid expenses	——	——	——	——	——
Change in accrued investment income	——	——	——	——	——
Net cash from operating activities	-$15.36M-7.9%	-$14.24M-10.5%	-$12.88M-11.4%	-$11.56M-14.7%	-$10.08M-38.5%
Capital expenditures	——	——	——	——	——
Acquired in-process research and development	$22.4M+36.9%	$16.36M+94.0%	$8.43M+43.2%	$5.89M+55.5%	$3.79M+33.4%
Net cash from investing activities	——	——	——	——	——
Proceeds from issuance of debt	——	——	——	——	——
Proceeds from issuance of common stock	——	——	——	——	——
Dividends paid on preferred stock	——	——	——	——	——
Net cash from financing activities	$13.6M+44.0%	$9.44M-29.4%	$13.37M-9.3%	$14.74M+12.3%	$13.13M+2.7%
Net increase (decrease) in cash	-$2.05M+61.0%	-$5.26M-27,063%	$19.52K-99.3%	$2.71M-5.9%	$2.88M-47.7%
Amortization	——	——	——	——	——
Stock-based compensation	$4.76M+11.6%	$4.27M+45.6%	$2.93M+38.5%	$2.11M—	——
Non-cash interest expense	——	——	——	——	-$275.62K-119%
Commitment Shares Issued For Equity Line Of Credit	——	——	——	——	——
Increase (Decrease) in Accrued Interest Receivable, Net	——	——	——	——	——
Other current liabilities	——	——	——	——	——
Increase (Decrease) in Prepaid Expense	——	——	——	——	——
Satisfaction of management and incentive fees in stock	$538.45K-9.6%	$595.84K-1.0%	$602.09K+63.1%	$369.09K+1.0%	$365.34K+1,361%
Net income	-$35.27M-22.7%	-$28.75M-57.3%	-$18.28M-28.0%	-$14.28M-26.4%	-$11.3M-26.8%
Shares Issued For Services	——	——	——	——	——
Proceeds From Royalties Received	——	——	——	——	——
Repayment Of Shareholder Loan	——	——	——	——	——
Dividends	——	——	——	——	——
Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants	——	——	——	——	$5.59M-7.6%
Proceeds From Related Party Debt	——	$134.18K-14.2%	$156.36K-12.4%	$178.53K-11.0%	$200.7K-9.9%
Proceeds From Warrant Exercises	——	——	——	——	——
Debt Instrument Issued Principal	——	$110K—	——	——	——
Earnings per common share - basic (in dollars per share)	-$1.08-9.1%	-$0.99+18.9%	-$1.22-2.5%	-$1.19+5.6%	-$1.26+5.3%
Earnings per common share - diluted (in dollars per share)	-$1.08-9.1%	-$0.99+18.9%	-$1.22-2.5%	-$1.19+5.6%	-$1.26+5.3%
Effective Income Tax Rate Reconciliation, Percent	——	——	——	——	——
Fair Value Adjustment Of Warrants	——	——	——	——	——
General and administrative costs	$11.47M-7.1%	$12.34M+9.7%	$11.25M+20.3%	$9.35M+26.4%	$7.4M+86.1%
Gross Proceeds	——	$2.5M—	——	——	——
Interest Expense, Nonoperating	——	——	——	——	——
Investment Income Interest	$228-8.4%	$249—	——	——	——
Milestone Payments	——	——	——	——	$39.16M+75.0%
Other Income - Net	-$1.4M-2,807%	-$48.14K-103%	$1.4M+45.5%	$962.08K+917%	-$117.7K+94.3%
Operating Income Loss	-$33.87M-18.0%	-$28.71M-45.8%	-$19.68M-29.1%	-$15.24M-36.3%	-$11.18M-64.1%
Original Issue Discount	——	——	——	——	——
Other Research And Development Expense	——	——	——	——	$65.02K-25.0%
Payments For Fees	$466.05K+75.0%	$266.32K—	——	——	——
Net proceeds from sale of equity interest	$3.77M+612%	$530.16K—	——	——	——
Professional services	$26.47K+75.0%	$15.13K—	——	——	——
Rent Expense	$9.67K-6.9%	$10.39K+74.6%	$5.95K-6.8%	$6.39K+43.1%	$4.46K+155%
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate	——	——	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate	——	——	——	——	——
Issuance of common stock for the acquisition of Ansys	——	——	——	——	——
Upon redemption of Accenture Holdings plc ordinary shares	——	——	——	——	——
Diluted (in shares)	125M+16.2%	107.6M+26.2%	85.3M+23.2%	69.2M+38.2%	50.1M+43.8%
Free cash flow	——	-$14.7M—	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does OS Therapies generate?: OS Therapies (OSTX) generated -$15.4M in operating cash flow over the trailing twelve months.
What is OS Therapies's free cash flow?: OS Therapies's free cash flow was -$14.7M over the trailing twelve months.
Where does OS Therapies's cash flow data come from?: Every line is extracted from OS Therapies's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.